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Abstract
Background: Probiotics such as bifidobacteria have been shown to maintain a healthy intestinal
microbial balance and help protect against infections. However, despite these benefits,
bifidobacteria still remain poorly understood at the biochemical, physiological and especially the
genetic level. Herein we describe, for the first time, the development of a non-invasive luciferase-
based reporter system for real-time tracking of Bifidobacterium species in vivo.
Results: The reporter vector pLuxMC1 is based on the recently described theta-type plasmid
pBC1 from B. catenatulatum [1] and the luxABCDE  operon from pPL2lux [2]. Derivatives of
pLuxMC1, harbouring a bifidobacterial promoter (pLuxMC2) as well as a synthetically derived
promoter (pLuxMC3) [3] placed upstream of luxABCDE, were constructed and found to stably
replicate in B. breve UCC2003. The subsequent analysis of these strains allowed us to assess the
functionality of pLuxMC1 both in vitro and in vivo.
Conclusion: Our results demonstrate the potential of pLuxMC1 as a real-time, non-invasive
reporter system for Bifidobacterium. It has also allowed us, for the first time, to track the
colonisation potential and persistence of this probiotic species in real time. An interesting and
significant outcome of the study is the identification of the caecum as a niche environment for B.
breve UCC2003 within the mouse gastrointestinal tract (GI) tract.
Background
The human small and large bowel accommodates bacteria
belonging to more than 400 known species, many of
which play a mutualistic role in the digestion of dietary
nutrients [4]. The concept of probiotic bacteria has
evolved from a live active culture which improves the bal-
ance of the gut microbiota composition, to one that incor-
porates specific beneficial effects, including maturation of
the mucosal adaptive immune system [5]. Indeed con-
sumption of probiotics such as bifidobacteria has been
shown to maintain a healthy intestinal microbial balance
and help protect against intestinal infections [6-8]. A sig-
nificant goal of current research is to understand the com-
plex nature of the probiotic interaction with the innate
immune system. This ability to direct and modulate the
immune system has significant implications in the areas
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of atopic disease, cancer and pathogenesis [9]. However,
despite these potential beneficial properties and a grow-
ing industrial and consumer acceptance, bifidobacteria
still remain poorly understood at the biochemical, physi-
ological and especially the genetic level [10,11]. Current
efforts in the field of bifidobacterial genetics are focusing
on developing vectors for the genetic manipulation of the
species in vitro [12-14].
In order to confirm a strain-specific probiotic action it is
necessary to associate a given health-promoting function
with expression of a particular gene product(s). Gene
reporter fusions have been used for decades to identify
and monitor gene expression [15-18]. Traditional reporter
systems, based on enzymatic assays, are often limited to in
vitro retrospective analysis, typically involving cell disrup-
tion and addition of an enzymatic substrate followed by
an absorbance measurement. To date, the promoterless
gusA gene is the only successful reporter system utilized
for Bifidobacterium [13,18-20] and although valuable for
in vitro analysis of gene expression, it is limited by the fact
that it is semiquantative and cannot be applied in an in
vivo model.
A novel reporter system based on quantified light emis-
sion (bioluminescence) as a result of lux gene expression
has achieved considerable attention in recent times [21].
Light generation in naturally occurring bioluminescent
bacteria is encoded by five essential genes organized in an
operon such as luxCDABE. Blue-green light is emitted
from these bacteria with a peak at 490 nm as a result of a
heterodimeric luciferase, an enzyme which catalyses the
oxidation of reduced flavin mononucleotide (FMNH2)
and a long-chain fatty aldehyde (synthesized by a fatty
acid reductase complex encoded by luxCDE). Although a
number of additional lux genes have been identified, only
luxA-E are essential for the biosynthesis of light [22]. To
date the lux operon has been successfully expressed in a
variety of Gram-negative bacteria, conferring a biolumi-
nescent phenotype [23]. Since all identified species of nat-
urally occurring marine and terrestrial bioluminescent
bacteria are Gram-negative, the generation of Gram-posi-
tive bioluminescent bacteria has been limited. However,
the introduction of Gram-positive ribosome binding sites
and shuffling of the gene order to luxABCDE  [24] has
facilitated the successful application of the luciferase sys-
tem in a limited number of Gram-positive bacteria
[22,25,26].
A recent study by Guglielmetti [27] reported the use of
insect luciferase in B. longum biovar longum as a biosensor
to analyze the metabolic state of cells. Herein we describe
for the first time the development of a Lux (bacterial luci-
ferase) based reporter system for the species Bifidobacte-
rium. The reporter vector pLuxMC1 is based on the
recently described theta based plasmid pBC1 from B. cat-
enatulatum [1] and the luxABCDE operon from pPL2lux
[2]. Derivatives of pLuxMC1, harbouring a bifidobacterial
promoter (pLuxMC2) as well as a synthetically derived
promoter (pLuxMC3) [3] placed upstream of luxABCDE,
were constructed and found to stably replicate in B. breve
UCC2003, a strain originally isolated from nursling stool.
The subsequent analysis of these strains allowed us to
assess the functionality of pLuxMC1 both in vitro and in
vivo. Our results demonstrate the potential of pLuxMC1 as
a real-time, non-invasive reporter system for Bifidobacte-
rium. It has also allowed us, for the first time, to track the
colonisation potential and persistence of this probiotic
species in real time. An interesting and significant out-
come of the study is the identification of the caecum as a
niche environment for B. breve UCC2003.
Results
Construction of the luciferase based reporter system 
pLuxMC1
The pLuxMC1 vector (Fig. 1) is a derivative of the shuttle
vector pBC1.2 [14] that contains a putative theta-type rep-
lication origin and a chloramphenicol (Cm) resistance
marker. In addition, pLuxMC1 contains luxABCDE, a syn-
thetic operon that contains optimized Gram-positive
translational initiation sequences upstream of luxA, luxC
and luxE [24]. The luxABCDE operon is divergently orien-
tated with respect to flanking genes on pLuxMC1 to min-
imize any potential read-through from upstream
promoters. Importantly, the use of the SalI and SwaI
restriction sites for cloning of PCR-amplified promoters
into pLuxMC1 allowed the creation of transcriptional
fusions to the luxABCDE operon. Furthermore, since the
ribosomal binding site and start codon of luxA are absent
in pLuxMC1, such fusions are also required to include
appropriate translational start signals, and thus allow
direct identification of correct expression signal insertions
by their bioluminescent phenotype in E. coli.
Functionality and stability of pLuxMC1 derivatives
To demonstrate the functionality of the pLuxMC1 luci-
ferase reporter system in B. breve UCC2003, the expres-
sion profiles of two promoters and associated
translational signals were assessed. The first of these (Prep)
is the promoter driving the expression of the repC gene
from the cryptic B. catenulatum plasmid pBC1. The second
is a constitutive optimised promoter (Phelp), from Listeria
monocytogenes, where it has been shown to elicit constitu-
tively high activity [3]. Vectors pLuxMC2 and pLuxMC3
containing each of these promoters respectively, were con-
structed in E. coli and transformed into B. breve UCC2003
as described in Materials and Methods.BMC Microbiology 2008, 8:161 http://www.biomedcentral.com/1471-2180/8/161
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The stability of all constructs in the absence of antibiotic
selection pressure was evaluated. Cultures of B. breve
UCC2003 containing pLuxMC1, pLuxMC2 or pLuxMC3,
were grown for 100 generations in MRS medium without
antibiotic selection, after which dilutions were plated
every 20 generations to assess the presence of the plasmids
in the resulting colonies by scoring for Cm resistance
encoded by the pBC1.2 backbone. All 100 colonies tested
for each of the three strains at each of the time points were
Cm-resistant (data not shown), indicating that the plas-
mids were stably maintained without antibiotic selection
pressure for at least 100 generations under the conditions
tested. This high level of stability allowed use of the luci-
ferase reporter system in animal experiments in which
antibiotic selection pressure could not be maintained.
Overnight cultures of the pLuxMC-containing B. breve
strains were diluted 1:50 in MRS medium supplemented
with cysteine HCl. Growth and bioluminescence were
then monitored over time (Fig. 2). No difference in
growth rates or final optical density were detected
between B. breve UCC2003 harbouring either pLuxMC2,
pLuxMC3 or pLuxMC1, indicating that luciferase expres-
sion at the levels reached during the experiments
described here does not influence the growth rate of B.
breve UCC2003. No bioluminescence was detected at any
time for the control strain B. breve UCC2003 containing
pLuxMC1, demonstrating the absence of any background
signal (data not shown). For the B. breve strain harbouring
pLuxMC3, bioluminescence was detected throughout all
growth stages, indicating constitutive expression of the lux
operon (Fig. 2). In contrast, for pLuxMC2 biolumines-
cence declined during the late logarithmic phase of
growth and further decreased in the stationary phase,
until the signal eventually became undetectable. This sig-
nificant difference in bioluminescence profiles observed
for pLuxMC2 and pLuxMC3 during stationary phase sug-
gests that differential expression can be monitored in B.
breve UCC2003 using the luciferase reporter system.
Expression in a murine model
The suitability of the pLuxMC1 reporter system to moni-
tor gene expression in vivo was investigated in the gas-
trointestinal tract of mice. Three groups of three mice were
orally inoculated with B. breve UCC2003 containing
either pLuxMC1, pLuxMC2 or pLuxMC3. Whole body
image analysis was performed 5 days following the final
inoculation. No distinct luminescent signal was observed
for any of the groups which may be explained by the find-
ings of Rice et al, [28] who reported that cell numbers in
excess of 106 are required to detect signals at 2 cm depth
in tissue. Shedding of B. breve UCC2003 containing the
pLuxMC derivatives in the faeces was detected throughout
the twelve-day trial period. The administered bacterial
populations increased in number in the faecal samples up
to day 5, reaching a plateau at approximately 107 cfu g-1
stool, declining to around 105 cfu g-1 stool at day 12 post
inoculation (Fig. 3). Nine days following initial inocula-
tion the mice were sacrificed by cervical dislocation, and
the levels of bioluminescence in the intact GI tracts were
determined and correlated with the numbers of bacterial
cells recovered on selective medium (Fig. 4). Notably, the
numbers of CFU recovered from the mice inoculated with
all three strains were very similar, suggesting that luci-
ferase expression does not influence the persistence of B.
breve UCC2003. The results also confirm that the biolumi-
nescence data is quantitative, correlating with the number
of bacteria present. However, viable counts were found to
have higher limits of detection than luminometry. No
bioluminescence was detected in the GI tracts of the three
mice in the control group. In contrast, the caecum
obtained from the two groups of mice fed with either B.
breve  UCC2003 pLuxMC2 or UCC2003 pLuxMC3 dis-
played relatively high levels of bioluminescence. The
detection limits of the IVIS100 imaging system (Xenogen)
were determined to be approximately 103 bacteria within
a given focus, which correlates well with previous studies
[29]. Interestingly, in contrast to the in vitro expression
profile, both vectors were detected to an equal extent in
the gastrointestinal tract after 12 days. The data clearly
demonstrate the usefulness of the pLuxMC reporter sys-
tem to monitor bifidobacterial gene expression in the
murine GI tract.
Plasmid map of pLuxMC Figure 1
Plasmid map of pLuxMC. pBC1.2 is bifidobacterial shuttle 
vector containing a chloramphenicol-resistance cassette [14]. 
The luxABCDE operon with a blunt SwaI restriction site over-
lapping the luxA start codon was derived from pPL2lux [2].
pLuxMC1
6000
pBC1.2BMC Microbiology 2008, 8:161 http://www.biomedcentral.com/1471-2180/8/161
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Dynamics of colonization and persistence of B. breve 
UCC2003
Colonization and clearance of B. breve UCC2003 harbour-
ing pLuxMC1 (hereafter referred to as control) or
pLuxMC2 (test) was monitored over a thirty-three day
period by following bioluminescence and viable counts
recovered from both the GI tract and faecal samples. Two
groups of mice (n = 5) were orally inoculated with either
the control or test strain. Shedding of B. breve UCC2003
control and test strains in the faeces was detected through-
out the trial with no statistically significant differences
observed between the two groups. The inoculated bacte-
rial population increased in number (Fig. 5), reaching a
maximum of ~107 cfu g-1 faeces at day 5, from day 10–19
the level of UCC2003 shed plateaus at ~105 cfu g-1 faeces.
Following day 19 there is a steady decline to ~104 cfu g-1
until days 31 and 33 when a marginal increase in faecal
shedding was observed.
On day 5, the GI tract recovered from a single test animal
showed detectable bioluminescence originating from
both the lower small intestine and the caecum, with little
signal detectable in the colon. Viable counts of both stool
and tissue samples taken on day 5 from both test and con-
trol fed mice revealed that B. breve UCC2003 was present
within the colonic mucosa, suggesting that at this time
point microcolonies, consisting of at less than 103 bacteria
had formed. Within 2 days of inoculation, the majority of
the bolus of bacteria had travelled through the gut, with
some of the inoculum remaining in the lower small intes-
tine; bioluminescence on day 5 from this portion of the
GI tract corresponded with the presence of a large food
bolus. After the initial bolus had passed no detectable
B. breve UCC2003 pLuxMC1-3 recovered from murine stool Figure 3
B. breve UCC2003 pLuxMC1-3 recovered from 
murine stool. Recovery of B. breve UCC2003 pLuxMC 
derivatives from murine stool samples over a 12 day trial 
period. The data are representative of the average colony 
forming units per gram of faeces from three faecal samples 
per group per time point (days).
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Growth and expression profiles for B. breve UCC2003 pLuxMC derivatives. Growth and expression of UCC2003 
pLuxMC1, pLuxMC2 and pLuxMC3 during growth at 37°C in MRS medium supplemented with cysteine-HCL and chloram-
phenicol. The line graphs indicate the average growth of triplicate cultures and the grey and black bars indicate the average luci-
ferase expression profiles for pLuxMC2 and pLuxMC3 respectively. BLU is the bioluminescence counts measured as photons 
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luminescence was observed from the small intestine and
the level of bacteria detected by viable counts fell to ~103
cfu g-1.
While B. breve UCC2003 numbers remained detectable by
viable colony counts, verified by colony PCR, for both the
small intestine and colonic samples at day 12, 19, 26 and
day 33 the counts remained close to 103 cfu g-1 tissue
which is below the limits of bioluminescence detection of
the Xenogen IVIS100 system for intact organs. Interest-
ingly, the caecum remained colonised throughout the trial
(Fig. 6, Fig. 7). Once again bioluminescence data strongly
correlated with the number of bacteria present in homog-
enized tissue samples. Colonisation of the caecum was
evident from day 5 and by day 12 the caecum was the only
portion of the GI tract where bioluminescence could be
detected corresponding to a log increase in the number of
CFU. Colonisation of the caecum peaked at day 19 and by
day 33 the caecum was the only portion of the GI tract
containing significant numbers of the inoculated bacteria
(105 cfu g-1). The reduced levels of B. breve UCC2003
observed in the caecum at day 33 correlated with a mar-
ginal increase in shedding observed on day 31 and 33 pos-
sibly reflecting the clearance of the administered B. breve
UCC2003 from the murine GI tract (Fig. 5).
Contribution of the native bifidobacterial population
Previous studies have reported native bifidobacterial pop-
ulations in the murine GI tract of 103 cfu g-1 for the small
intestine and 105 cfu g-1 for the colon including the cae-
cum [4]. To establish if this trend was evident throughout
the persistence study, aliquots of homogenised tissue
samples were plated on RCA containing mupirocin,
which has been previously reported as a selective agent for
Bifidobacterium [30]. Total bifidobacterial counts from the
caecum followed a similar trend to that of the inoculated
bacteria levels, beginning at 105 on day 5, rising to 108 by
day 19 before reducing to 105 at day 33. The bifidobacte-
rial population in the colon remained relatively constant
at ~105 while the small intestine showed an initial total
Comparison of pLuxMC1-3 colony forming units and bioluminescence from murine GIT samples nine days post-inoculation Figure 4
Comparison of pLuxMC1-3 colony forming units and bioluminescence from murine GIT samples nine days 
post-inoculation. Comparison of B. breve UCC2003 pLuxMC derivatives recovered from (a) the caecum; (b) the large intes-
tine and (c) the small intestine, each set of data is representative of the average values from three mice per group. The BLU 
(bioluminescence counts in photons per second) represented in grey refers to the bioluminescence recorded from the intact 
tissue sections upon excision 9 days post-inoculation and immediately prior to homogenization. The black bar is the average 
CFU (colony forming units) per ml of homogenized tissue sample.
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population of 106 on day 5 followed by a plateau at ~104
throughout the remainder of the trial. Random colonies
displaying bifidobacterial morphology which were not
chloramphenicol resistant were further analysed, chromo-
somal DNA was extracted and a PCR targeting the 16S
intergenic spacer region [32] allowed us to identify five
species of bifidobacteria native to these murine intestines
with blast homology to B. longum, B. adolescentis (small
intestine), B. animalis and B. animalis subsp lactis.
Discussion
In this study we describe the construction of a luciferase-
based reporter system, pLuxMC1, and the successful
application of this system to track B. breve UCC2003
growth in vitro (laboratory medium) and in vivo (murine
model). The vector pLuxMC1, similar to pPL2lux [2],
allows for the construction of exact translational/tran-
scriptional fusions of promoters to the luciferase-encod-
ing genes. As consensus promoters in the genus
Bifidobacterium are not well defined, we chose to evaluate
a native bifidobacterial expression signal (Prep), which is
located upstream of repC on the cryptic plasmid pBC1 and
which was previously shown to be essential for pBC1 rep-
lication [14]. We also examined Phelp  [3], a promoter
developed for constitutive gene expression in L. monocy-
togenes and a wide range of Gram-positive and Gram-neg-
ative species [31]. Both of the luciferase-expressing B.
breve  strains displayed growth characteristics similar to
those of control strains and no background biolumines-
cence was observed during any of the experiments. This
highlights the major advantage of luciferase-based
reporter systems when compared to the glucuronidase-
based reporter systems currently available for Bifidobacte-
ria [13,18-20].
One potential caveat to the use of the luciferase-based sys-
tem for B. breve is that the oxygen requirements for the
effective functioning of LuxABCDE have to be fulfilled by
an anaerobic bacterium in a supposedly anaerobic envi-
ronment [23]. The oxygen dependence of bacterial luci-
ferase has previously been critically studied in light of
certain in vivo imaging applications and we concur with
Hardy et al. [25] that the presence of a luminescent signal
at a particular site indicates that sufficient oxygen is
present for the reaction to occur, but that bacterial counts
should in the first instance be determined to confirm that
the level of luminescence is correlated to a certain number
of cells under a given set of experimental conditions. The
determination of a direct correlation was not possible
through whole-body imaging of B. breve UCC2003-inocu-
lated mice and indeed this analysis may not be possible
using the current system as, regardless of the light source,
transmission depends on the type of tissue and the depth
of the light source in the animal [29]. Future efforts to
obtain such images may involve imaging the mice at a
later stage of colonization, increasing lux expression levels
or increasing the cell densities through the exploitation of
bifidobacterial-specific growth promoting factors such as
non-digestible oligosaccharides [33].
The ability of B. breve UCC2003 to express a Lux+ pheno-
type  in vivo was initially investigated over a period of
twelve days using bioluminescence as well as viable count
measurements. Analysis of the two pLuxMC-containing
strains revealed that the in vitro expression profile was not
reflected in vivo. The Phelp promoter of pLuxMC3 gives sig-
nificantly higher bioluminescence expression to Prep of
pLuxMC2 (Fig 2) during stationary-phase growth under
laboratory conditions; however, under in vivo conditions
the difference in expression is no longer apparent indicat-
ing that in the murine model the native bifidobacterial
promoter Prep is as suitable to drive luciferase expression as
the constitutive promoter Phelp.
The luminescence of microbial cells is strongly dependent
on metabolic activity, making the Lux+ phenotype an indi-
cator of metabolic integrity [34]. During in vitro growth of
many bacterial species harbouring the lux operon, biolu-
minescence declines when cells enter stationary phase
[26]. This pattern of light production was observed in vitro
for B. breve UCC2003 containing pLuxMC2 and this may
be caused by a decrease in metabolic activity. The tight
correlation between luminescence and viable counts
obtained from both stool and organ homogenates during
colonisation of mice with B. breve UCC2003 suggests that,
similar to what has previously been reported for Citro-
bacter rodentium [29], colonizing bacteria are metaboli-
cally similar to those seen during the exponential phase of
in vitro growth and that intracellular cofactors are not lim-
iting.
Persistence of B. breve UCC2003 pLuxMC derivatives in the  murine GIT Figure 5
Persistence of B. breve UCC2003 pLuxMC derivatives 
in the murine GIT. The log of colony forming units of B. 
breve UCC2003 containing either pLuxMC1 ( ) or pLuxMC2 
( ) per gram of faeces over 33 day trial period. The data is 
representative of duplicate plating from the available feacal 
samples at each given time point. On day one to three the 
mice were orally gavaged with 109 B. breve UCC2003 con-
taining either pLuxMC1 (control) or pLuxMC2 (test).
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The bioluminescent B. breve UCC2003::pLuxMC2 was
subsequently exploited to investigate in situ and in real
time, the dynamics of colonization of orally inoculated
mice over a 33-day period. The short half-life (several sec-
onds) of the luciferase enzyme [35], coupled with a very
low level of background luminescence in mammalian tis-
sue makes bioluminescence an excellent reporter system
for analysing colonization of a host intestine by bacteria
as observations occur in real time and do not reflect accu-
mulated signal.
The most striking finding of this study is that primary col-
onization of the mouse by B. breve UCC2003 takes place
within the caecum. Although bifidobacterial species have
previously been isolated at 105 CFU/g from pig caecal con-
tents [30], 103 CFU/g from rabbit [36], 106 CFU/ml from
human [37], and 109 CFU/g from hen [36], this is the first
time that the caecum has been implicated as the predom-
inant colonization site for these bacteria. Interestingly,
pathogens such as EHEC O157:H7 [38] and C. rodentium
[29] also exhibit murine caecal colonization. Histologi-
cally the organisation of the caecum is similar to Peyer's
patches (PPs) with domed villi containing M cells and
dendritic cells. A variety of pathogens exhibit a tropism for
PP. Following adhesion, enteroinvasive Yersinia, Shigella,
and  Salmonella  sp. enter PP and are able to multiply
within this tissue [39]. In S. typhimurium targeting of the
pathogen to PP is mediated by surface components
including the long polar fimbriae which when inactivated
impairs the colonization of murine PP [40]. The first stage
of colonization within the caecal patch of the mouse
intestine by C. rodentium is also proposed to be mediated
by the synergistic action of fimbriael operons [41].
Correlation between bioluminescence and colony forming units (pLuxMC1) Figure 6
Correlation between bioluminescence and colony forming units (pLuxMC1). Illustrates the log colony forming units 
per ml from groups of mice feed pLuxMC1 for three days followed by thirty days of persistence study. The recovered gastroin-
testinal tracts (GIT) at each of the five time points were divided into the major physical sections and the average cfu/ml from 
the homognised tissue samples are represented in red ( ) for the caecum, yellow ( ) for the large intestine and the small intes-
tine in blue ( ). The image panel in both (a) and (b) represents an intact excised GIT at each time point. These images were 
obtained using an IVIS 100 system with 5 min of exposure and a binning value of 8. The color bar indicates the bioluminescence 
signal intensity (in photons s-1 cm -2 sr-1). ND, not detectable (bioluminescence counts less than 1 × 104 photons s-1). BLU, bio-
luminescence counts (photons s-1 cm -2 sr-1); BLU C, recovered from caecum; BLU LI, from the large intestine and BLU SI from 
the small intestine.
1.00E+00
1.00E+01
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
Day 5 Day 12 Day 19 Day 26 Day 33
Time (days)
L
o
g
 
c
f
u
/
m
l
Cecum
Large Int
Small Int
BLU: ND BLU: ND BLU: ND BLU: ND BLU: ND
Day 33 Day 26 Day 19 Day 12 Day 5
Caecum (C)
Large Int (LI)
Small Int (SI)BMC Microbiology 2008, 8:161 http://www.biomedcentral.com/1471-2180/8/161
Page 8 of 12
(page number not for citation purposes)
The caecum may be the site which allows certain patho-
gens to adapt to the intestinal environment, and where
genes required for efficient colonization of the colon are
activated [42]. The caecum may also act as a reservoir,
shedding bacteria into the colon. It is interesting to note
that for C. rodentium the caecal patch is also the first site to
be cleared of infection and that clearance of the colon fol-
lows shortly afterwards [29]. Evidence exists that the best
protection against mucosal attachment and invasion by
such pathogens is by keeping intestinal microbiota in a
state that affords colonisation resistance against patho-
gens by modulation of the microbiota inducing luminal
or systemic effects which are beneficial to the host's health
[43]. It is conceivable that B. breve UCC2003 may act
through competitive exclusion in the caecum, at least in
the murine model, and that their presence may prevent
pathogenic bacteria from becoming established.
Conclusion
The application of pLuxMC1 derivatives has significant
potential to allow further study of the interaction of bifi-
dobacteria with a mammalian host. The system has the
distinct advantage of allowing direct comparison of differ-
ent promoter activities in intact animal tissue. This
reporter system is a valuable addition to the arsenal of
genetic tools available for bifidobacteria as it can be
employed for in situ real-time investigation of promoter
activities both in vitro and in vivo. Currently, the luciferase
reporter system is being exploited in our laboratory to
explore expression profiles for B. breve UCC2003 chromo-
somal genes to further our understanding of transcription
Correlation between bioluminescence and colony forming units (pLuxMC2) Figure 7
Correlation between bioluminescence and colony forming units (pLuxMC2). Illustrates the log colony forming units 
per ml from groups of mice feed pLuxMC2 for three days followed by thirty days of persistence study. The recovered gastroin-
testinal tracts (GIT) at each of the five time points were divided into the major physical sections and the average cfu/ml from 
the homognised tissue samples are represented in red ( ) for the caecum, yellow ( ) for the large intestine and the small intes-
tine in blue ( ). The image panel in both (a) and (b) represents an intact excised GIT at each time point. These images were 
obtained using an IVIS 100 system with 5 min of exposure and a binning value of 8. The color bar indicates the bioluminescence 
signal intensity (in photons s-1 cm -2 sr-1). ND, not detectable (bioluminescence counts less than 1 × 104 photons s-1). BLU, bio-
luminescence counts (photons s-1 cm -2 sr-1); BLU C, recovered from caecum; BLU LI, from the large intestine and BLU SI from 
the small intestine.
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signals in this strain (unpublished data). The wealth of
information regarding gene expression that will become
available from this type of approach is expected to con-
tribute significantly to understand the molecular mecha-
nisms underlying B. breve UCC2003 behaviour in situ.
Methods
Bacterial strains, plasmids and culture conditions
Bacterial strains, plasmids and primers used in this study
are listed in Table 1. E. coli strain TOP10 (Invitrogen, Pais-
ley, United Kingdom) was used as a cloning host for the
construction of pLuxMC1 and its derivatives (see below)
and was grown aerobically at 37°C in LB medium [44]. B.
breve UCC2003 was routinely grown at 37°C in reinforced
clostridial medium (Oxoid, Basingstoke, United King-
dom). However, for bioluminescence assays MRS
medium (Oxoid), supplemented with 0.05% (w/v)
cysteine-HCl was used. Anaerobic conditions were main-
tained using an anaerobic chamber [Mac500, Don Whit-
ley Scientific, West Yorkshire, UK (atmosphere 10% H2,
10% CO2, 80% N2)]. Where appropriate, antibiotics were
added to the growth media at the following concentra-
tions: for E. coli, ampicillin at 100 μg ml-1 or chloram-
phenicol at 20 μg ml-1; for B. breve, chloramphenicol at 4
μg ml-1. To facilitate specific recovery of bifidobacteria
from intestinal samples, 50 mg of mupirocin (Oxoid)/
liter was added to reinforced clostridial agar (Oxoid) from
antimicrobial susceptibility test discs, as previously
described [30].
DNA techniques
Plasmid DNA was isolated from E. coli using a QIAprep
Spin Miniprep kit according to the manufacturer's instruc-
tions (QIAGEN, Crawley, United Kingdom). Genomic
DNA isolation and transformation of B. breve UCC2003
were performed as described previously [45]. Standard
procedures were used for DNA manipulation in E. coli
[46]. Restriction endonucleases (Roche Diagnostics, Man-
nheim, Germany), T4 DNA ligase (Roche), and 2× PCR
mixture (Promega, Madison, WI) were used as recom-
mended by the manufacturers. Primers were purchased
from MWG (Ebersberg, Germany) and are listed in Table
1. PCR products that needed to be cloned were obtained
with KOD hot-start high-fidelity DNA polymerase
(Merck, Nottingham, United Kingdom).
Construction of pLuxMC1, pLuxMC2 and pLuxMC3
The vector pPL2lux [2] containing a unique SwaI restric-
tion site that overlaps the start codon of luxA, allowing
translational fusions between bifidobacterial expression
signals to the luxABCDE operon, was digested with SalI
and PstI to excise the 5.6 kb modified luxABCDE operon.
This was ligated into similarly digested pUC19 and cloned
into TOP10. This newly created plasmid was named
pUC19-lux. In order to create a control vector which does
not contain a promoter in front of luxABCDE, the operon
was excised from pUC19-lux as a PstI/SmaI fragment,
ligated into PstI and EcoRV-digested pBC1.2 [14] to create
pLuxMC1, which was generated using TOP10 as the clon-
ing host, and which was then introduced into B. breve
UCC2003 by electroporation.
Table 1: Bacterial strains, plasmids and primers used in this study.
Bacterial strains Relevant properties Source/Reference
Escherichia coli TOP10 F-mcrA φ80lacZ_M15 lacX74recA1araD galU rpsL endA1 nupG Invitrogen, UK.
Bifidobacterium breve UCC2003 Electroporation host UCC Culture Collection.
Plasmids Relevant properties Source/Reference
pPl2lux Allows for translational fusions to luxABCDE operon [2]
pUC19 2.686 kb vector based on pMB1, Ampr Fermentas
pUC19-lux pUC19 containing the 5.6 kb modified luxABCDE operon as SalI – PstI fragment. [2]
pBC1.2 Bifidobacterial shuttle vector based on pBC1, Cmr [14]
pLuxMC1 pBC1.2 containing the modified luxABCDE operon This study
pLuxMC2 pBC1.2 containing the luxABCDE operon plus promoter of repC from pBC1 This study
pLuxMC3 pBC1.2 plus luxABCDE operon with Phelp [3]. This study
Primers Sequence Source/Reference
IM111 Aaaaggacgatttcggttgg [2]
IM112 Ccaatgccccagaaatttcc [2]
Prep F Ccatccaactcgaggcacaagccgcgcgagcggtc This study
Prep R Catgggcactagtgtacgtc This study
Ampr, ampicillin resistance; Cmr chloramphenicol resistance. Underlining indicates restriction sites used in subsequent cloning stepsBMC Microbiology 2008, 8:161 http://www.biomedcentral.com/1471-2180/8/161
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The putative promoter region of repC from the B. catenu-
latum plasmid pBC1 [1] was PCR amplified and digested
with SalI. The resulting 0.5-kb PCR product (Prep) encom-
passed the region immediately upstream of the replica-
tion gene. Notably, the start codon of the repC  was
included at the ultimate 3' end of the reverse primer. This
fragment was ligated into pUC19-lux digested with SwaI/
SalI and cloned into TOP10. Isolates producing light (as
monitored by the IVIS100, Xenogen) were subjected to
restriction and PCR analysis. The plasmid content of one
clone was subsequently sequenced and shown to repre-
sent the expected fusion. This plasmid was digested with
PstI/SmaI, ligated into pBC1.2 [14] which had been
digested with PstI/EcoRV, creating pLuxMC2, and cloned
into TOP10. Plasmid DNA from a clone with the correct
restriction profile was concentrated (1 μg) and electropo-
rated in B. breve UC2003. A single chloramphenicol-resist-
ant transformant was selected based on its verified
genotype and used for subsequent bioluminescence activ-
ity determinations.
The promoter PCP25 is a highly active, constitutive lacto-
coccal consensus promoter [47] which was synthesized by
'gene tiling' [48]. Riedel et al [3] exploited PCP25 to create
Phelp (highly expressed Listeria promoter) by introducing
the 5' UTR (untranslated region) of the L. monocytogenes
EGDe  hlyA gene into PCP25  using the 'gene tiling'
approach. The Phelp promoter was cloned into pPL2lux [2]
as an exact translational fusion to luxABCDE creating
pPL2luxPhelp. This modified luxABCDE operon, contain-
ing the constitutive Phelp  promoter, was excised from
pPL2luxPhelp as an XhoI/PstI fragment and ligated into
pBC1.2 digested with PstI/SalI, creating pLuxMC3, and
cloned into TOP10. In the same manner as for pLuxMC2,
plasmid DNA from a pLuxMC3 clone with the correct
restriction profile was electroporated in B. breve UC2003
and assessed for subsequent bioluminescence activity
assays.
Plasmid stability studies
B. breve UCC2003 containing pLuxMC1, pLuxMC2 or
pLuxMC3 were first cultured in MRS broth containing 4
μg ml-1 chloramphenicol (Cm). Cells were then subcul-
tured in fresh MRS broth without antibiotic selection for
a total of 100 generations. Vector segregation stability was
monitored by plating for isolated colonies every 20 gener-
ations and spot inoculating 100 colonies onto RCA agar
plates with and without 4 μg ml-1 Cm and incubating at
37°C for 24 h. The percentage loss of the test plasmid in
the population was then calculated.
Oral inoculation of mice
Inocula were prepared by growing B. breve UCC2003 con-
taining either pLuxMC2, pLuxMC3 or the control vector
pLuxMC1 anaerobically overnight at 37°C in 100 ml of
MRS broth containing 4 μg ml-1 Cm. Strains were tested in
6–8 week old female BALB/c mice. Animals were kept in a
conventional animal colony and all experiments were
approved by the animal ethics committee of University
College Cork. Cultures were harvested by centrifugation
(7,000 × g for 5 min), washed with PBS supplemented
with 0.05% cysteine HCl (Sigma), and resuspended in a
one-tenth volume of PBS. Colonization of bifidobacteria
was established by three consecutive daily administra-
tions whereby each animal received 20 μl of ~109 cells
using a micropipette tip placed immediately behind the
incisors [49]. The viable count of each inoculum was
determined by retrospective plating on RCA agar contain-
ing 4 μg ml-1 Cm.
Comparison of pLuxMC2 and pLuxMC3 in vivo
To assess the functionality of the pLuxMC plasmids in
vivo, three groups, each containing three eight-week old
female BALB/c mice, were orally inoculated with B. breve
UCC2003 containing either pLuxMC1 (negative control),
pLuxMC2 or pLuxMC3. Three days post-inoculation the
animals were anesthetised with isofluorane and whole-
body image analysis was performed in the Xenogen IVIS
100 system for 5 minutes at high sensitivity. Stool samples
were recovered aseptically on each of the feeding days
(day 1 to 3) and subsequently on days 5, 8, 10 and 12, and
examined for bioluminescence using a Xenogen IVIS 100
system, weighed and resuspended in PBS at 0.1 g ml-1. In
order to estimate the number of bifidobacteria harbour-
ing a pLuxMC derivative per gram of faeces, individual
faecal samples were serially diluted and cultured on selec-
tive agar (RCA containing Cm 4 μg ml-1). On day 12 the
animals were sacrificed by cervical dislocation, their indi-
vidual gastrointestinal (GI) tracts were removed and these
were examined for bioluminescence. Following imaging,
the small intestine, caecum and large intestines were indi-
vidually homogenized in sterile PBS supplemented with
0.05% cysteine-HCl and serial dilutions were plated in
duplicate onto RCA agar containing 4 μg ml-1 Cm. The
resulting colonies were used to calculate the number of
bacterial cells per tissue sample.
Persistence of B. breve UCC2003::pLuxMC2 in the murine 
model
Following the comparative study detailed above, B. breve
UCC2003 pLuxMC2 was selected to investigate the per-
sistence of the strain in an animal model over a 33-day
period. Two groups, each containing five eight-week old
female BALB/c mice, were orally inoculated on day 1 to 3
as described in the previous section with either B. breve
UCC2003 harbouring pLuxMC1 or B. breve UCC2003
containing pLuxMC2. Stool samples were recovered asep-
tically three times a week for five weeks post-inoculation,
examined for bioluminescence using the Xenogen IVIS
100 system, weighed and resuspended in PBS at 0.1 g ml-BMC Microbiology 2008, 8:161 http://www.biomedcentral.com/1471-2180/8/161
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1. In order to estimate the number of B. breve UCC2003
cells per gram of faeces, individual faecal samples were
serially diluted and cultured on selective agar (RCA Cm 4
μg ml-1).
At selected time points, initially day 5 (two days post-feed-
ing), and subsequently every 7 days (day 12, 19, 26 and
33), one animal per group was sacrificed by cervical dislo-
cation, followed by the removal of the gastrointestinal
(GI) tract, which was then examined for bioluminescence.
The small intestine, caecum and large intestines were indi-
vidually homogenized in sterile PBS supplemented with
0.05% cysteine-HCl and serial dilutions were plated in
duplicate onto RCA agar containing Cm to calculate the
number of B. breve UCC2003 cells per tissue sample. Fol-
lowing enumeration of B. breve UCC2003 cells in tissue or
faecal samples, 100 random colonies were tested for the
presence of the plasmid by colony PCR using primers
IM111 and IM112 (Table 1). The contribution of the
native flora to the total bifidobacterial population was
also estimated, by plating dilutions from tissue samples
onto RCA containing mupirocin (Oxoid). After incuba-
tion, random isolates were spot inoculated onto RCA con-
taining either Cm 4 μg ml-1 or mupirocin; colonies failing
to replicate on RCA Cm 4 μg ml-1 were predicted not to be
B. breve UCC2003 though typical bifidobacterial mor-
phology was observed following microscopic analysis.
Species identification of these host-specific strains was
achieved using primers targeting the spacer region [32].
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